Marino Stram & Associates LLC Reduces Holdings in Pfizer Inc. (NYSE:PFE)

Marino Stram & Associates LLC trimmed its stake in Pfizer Inc. (NYSE:PFE) by 6.1% in the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The firm owned 47,173 shares of the biopharmaceutical company’s stock after selling 3,082 shares during the period. Marino Stram & Associates LLC’s holdings in Pfizer were worth $1,251,000 as of its most recent SEC filing.

Other institutional investors and hedge funds have also recently modified their holdings of the company. Viking Fund Management LLC lifted its position in Pfizer by 11.6% during the 4th quarter. Viking Fund Management LLC now owns 384,000 shares of the biopharmaceutical company’s stock valued at $10,188,000 after acquiring an additional 40,000 shares during the period. MBM Wealth Consultants LLC increased its stake in Pfizer by 8.5% during the 4th quarter. MBM Wealth Consultants LLC now owns 9,347 shares of the biopharmaceutical company’s stock valued at $249,000 after purchasing an additional 729 shares in the last quarter. Missouri Trust & Investment Co increased its stake in Pfizer by 3.6% during the 4th quarter. Missouri Trust & Investment Co now owns 51,757 shares of the biopharmaceutical company’s stock valued at $1,373,000 after purchasing an additional 1,801 shares in the last quarter. Bourgeon Capital Management LLC increased its stake in Pfizer by 610.3% during the 4th quarter. Bourgeon Capital Management LLC now owns 418,658 shares of the biopharmaceutical company’s stock valued at $11,107,000 after purchasing an additional 359,721 shares in the last quarter. Finally, Octavia Wealth Advisors LLC increased its stake in Pfizer by 49.3% during the 4th quarter. Octavia Wealth Advisors LLC now owns 22,159 shares of the biopharmaceutical company’s stock valued at $588,000 after purchasing an additional 7,319 shares in the last quarter. 68.36% of the stock is owned by hedge funds and other institutional investors.

Pfizer Stock Performance

Pfizer stock opened at $26.01 on Thursday. The company has a 50 day moving average price of $26.09 and a 200-day moving average price of $27.97. The company has a debt-to-equity ratio of 0.63, a quick ratio of 0.73 and a current ratio of 1.00. Pfizer Inc. has a fifty-two week low of $24.48 and a fifty-two week high of $31.54. The company has a market capitalization of $147.40 billion, a PE ratio of 35.15, a P/E/G ratio of 0.64 and a beta of 0.64.

Pfizer (NYSE:PFE) last posted its quarterly earnings results on Tuesday, October 29th. The biopharmaceutical company reported $1.06 earnings per share for the quarter, beating the consensus estimate of $0.64 by $0.42. Pfizer had a net margin of 7.07% and a return on equity of 16.28%. The firm had revenue of $17.70 billion during the quarter, compared to the consensus estimate of $14.92 billion. During the same quarter in the previous year, the firm posted ($0.17) earnings per share. The company’s revenue was up 31.2% on a year-over-year basis. As a group, equities analysts forecast that Pfizer Inc. will post 2.94 earnings per share for the current year.

Pfizer Increases Dividend

The firm also recently disclosed a quarterly dividend, which will be paid on Friday, March 7th. Investors of record on Friday, January 24th will be issued a dividend of $0.43 per share. This represents a $1.72 annualized dividend and a yield of 6.61%. This is a positive change from Pfizer’s previous quarterly dividend of $0.42. The ex-dividend date of this dividend is Friday, January 24th. Pfizer’s dividend payout ratio (DPR) is presently 227.03%.

Insider Activity at Pfizer

In other news, Director Scott Gottlieb purchased 1,000 shares of the business’s stock in a transaction on Wednesday, October 30th. The shares were acquired at an average cost of $28.24 per share, with a total value of $28,240.00. Following the completion of the acquisition, the director now owns 10,000 shares of the company’s stock, valued at $282,400. This trade represents a 11.11 % increase in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which can be accessed through the SEC website. 0.06% of the stock is currently owned by corporate insiders.

Wall Street Analyst Weigh In

A number of brokerages have recently commented on PFE. Bank of America reiterated a “neutral” rating and issued a $29.00 price target on shares of Pfizer in a research note on Tuesday, December 10th. Wolfe Research initiated coverage on shares of Pfizer in a research note on Friday, November 15th. They issued an “underperform” rating and a $25.00 price target for the company. Truist Financial cut their target price on shares of Pfizer from $36.00 to $32.00 and set a “buy” rating for the company in a research report on Wednesday, December 18th. Cantor Fitzgerald reissued an “overweight” rating and issued a $45.00 target price on shares of Pfizer in a report on Wednesday, October 23rd. Finally, UBS Group reduced their price target on shares of Pfizer from $31.00 to $29.00 and set a “neutral” rating on the stock in a research report on Wednesday, January 8th. One equities research analyst has rated the stock with a sell rating, eight have given a hold rating, six have assigned a buy rating and two have assigned a strong buy rating to the company’s stock. According to MarketBeat, Pfizer currently has a consensus rating of “Moderate Buy” and a consensus price target of $32.00.

About Pfizer

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.